A Pilot Study for Ilorasertib (ABT-348) in Patients With CDKN2A-deficient Advanced Solid Cancers: A Series of Individual Patient Cross-Over Studies With Growth Trajectory Assessment

Trial Profile

A Pilot Study for Ilorasertib (ABT-348) in Patients With CDKN2A-deficient Advanced Solid Cancers: A Series of Individual Patient Cross-Over Studies With Growth Trajectory Assessment

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Ilorasertib (Primary)
  • Indications Solid tumours
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 07 Aug 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
    • 07 Aug 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jun 2018.
    • 06 Jun 2017 Results of a pharmaco-kinetics/dynamics evaluation from NCT02540876 and NCT01110486 trials presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top